BioSpace News Archive

LENSAR, Inc. today announced that Nick Curtis, Chief Executive Officer will present at the H.C. Wainwright Ophthalmology Virtual Conference on August 17, 2021.

Masimo announced the findings of a study published in the Journal of Pain & Relief in which Dr. Jacques Chelly and colleagues at the University of Pittsburgh investigated the utility of Masimo Bridge®, an auricular field nerve stimulator, in reducing postoperative opioid requirements in patients undergoing kidney donor surgery.

ReCode Therapeutics today announced the appointment of Angèle Maki, Ph.D., as senior vice president, business development.

Halberd Corporation’s research at Youngstown State University caught the attention of Youngstown, OH TV news station, WKBN, a CBS affiliate.

Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced financial results for the second quarter ended June 30, 2021 and provided a corporate update.

Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today provides a business update and releases its financial results for the first fiscal quarter, ended June 30, 2021, of fiscal 2022.

Micron Solutions, Inc. (OTCQB: MICR) (the “Company”), a diversified contract manufacturing organization, through its wholly-owned subsidiary, Micron Products, Inc., producing highly-engineered, innovative components requiring precision machining and injection molding, announced results for its second quarter ended June 30, 2021.

Ultromics, a leader in AI enabled cardiovascular imaging solutions, announced that it has raised $33 million in a Series B funding round.

Sagimet Biosciences announced today that clinicians recently dosed the first patient with nonalcoholic steatohepatitis ( NASH ) in its FASCINATE-2 Phase 2b clinical trial.

Increasing cases of cancers in all worldwide locations is estimated to boost sales opportunities in the global non-invasive cancer therapies market during the tenure of 2020 to 2030.